Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV Raises EUR 31.5 Million in Private Placement
Ablynx NV (Ablynx) announced that it has raised EUR 31.5 million through a private placement of new shares via an accelerated bookbuilding procedure announced on February 27, 2013. The private placement has allowed Ablynx to place 4,377,919 new shares with a range of domestic and international institutional investors and qualified institutional buyers in the United States at a price of EUR 7.2 per share, a 6.7% discount on the previous closing price. This represents 10.0% of the current number of outstanding shares and will bring the total number of shares after the issue to 48,157,116. The new shares will be admitted to trading on NYSE Euronext Brussels following their issuance, which is expected to take place on March 5, 2013.
Latest Key Developments in Biotechnology
- CONTRAFECT CORP confirms appointment of Julia P. Gregory as CEO and Director
- Redhill Biopharma Ltd and IntelGenx provide an update on FDA's ongoing review of NDA for RHB-103 Oral Migraine Film
- Zogenix Inc announces sale of SUMAVEL DosePro Migraine Therapy to Endo International
- Epigenomics AG says partner BioChain completes clinical validation study for CFDA approval of Epi proColon in China
- Share this
- Digg this